Figures & data
Table 1 Demographic and clinical characteristics of the patients
Figure 1 Intravitreal injection intervals before and after the switch from ranibizumab to aflibercept.
![Figure 1 Intravitreal injection intervals before and after the switch from ranibizumab to aflibercept.](/cms/asset/d52bc41a-f8c0-481e-b4a9-56f179ff2c86/doph_a_128651_f0001_c.jpg)
Figure 2 Intravitreal injection intervals just before and after the switch from ranibizumab to aflibercept.
![Figure 2 Intravitreal injection intervals just before and after the switch from ranibizumab to aflibercept.](/cms/asset/9d847385-0244-4b69-90a9-48be0aefac0a/doph_a_128651_f0002_c.jpg)
Figure 3 CRT during the study period.
Abbreviation: CRT, central retinal thickness.
![Figure 3 CRT during the study period.](/cms/asset/df4fa6cc-e78e-4596-b414-020e5da69f75/doph_a_128651_f0003_c.jpg)
Figure 4 BCVA after the switch to aflibercept.
Abbreviations: BCVA, best-corrected visual acuity; logMAR, logarithm of minimal angle of resolution.
![Figure 4 BCVA after the switch to aflibercept.](/cms/asset/28b9db92-4d8f-4b89-84e7-1bba7d6a6a8f/doph_a_128651_f0004_b.jpg)